BACKGROUND: Thyroid cancer affects relatively young adults, and its overall survival is excellent. With long life expectancy, the development of subsequent cancers is an important concern for survivors of thyroid cancer. The objective of this study was to investigate the incidence and types of second primary malignancies in Korean patients with thyroid cancer. METHODS: The study cohort included 178,844 registrants with thyroid cancer from the Korea Central Cancer Registry (KCCR) database between 1993 and 2010. Standardized incidence ratios (SIRs) were calculated using a statistical software program (SEER*Stat 8.0.4). RESULTS: Among 178,844 patients with thyroid cancer, 2895 (1.6%) were diagnosed with subsequent second primary malignancies. The overall risks of a second primary cancer were elevated by 6% in patients who had thyroid cancer compared with the general population during the same period. The elevated risks for developing second cancers were observed in all sites except the stomach and cervix. The elevated risk of second primary cancers was observed within the first 10 years of follow-up. Leukemia and cancers of the salivary gland, kidney, prostate, lung, and breast had the most significantly elevated risks as secondary cancers and presented as early as during the first 5 years after the initial diagnosis of thyroid cancer. CONCLUSIONS: This is the largest, standardized, population-based study to date using nationwide data from the entire Korean population. The risks of several cancers were elevated significantly during follow-up, thus alerting physicians to pay special attention in their care of patients with thyroid cancer and long-term survivors.
BACKGROUND:Thyroid cancer affects relatively young adults, and its overall survival is excellent. With long life expectancy, the development of subsequent cancers is an important concern for survivors of thyroid cancer. The objective of this study was to investigate the incidence and types of second primary malignancies in Korean patients with thyroid cancer. METHODS: The study cohort included 178,844 registrants with thyroid cancer from the Korea Central Cancer Registry (KCCR) database between 1993 and 2010. Standardized incidence ratios (SIRs) were calculated using a statistical software program (SEER*Stat 8.0.4). RESULTS: Among 178,844 patients with thyroid cancer, 2895 (1.6%) were diagnosed with subsequent second primary malignancies. The overall risks of a second primary cancer were elevated by 6% in patients who had thyroid cancer compared with the general population during the same period. The elevated risks for developing second cancers were observed in all sites except the stomach and cervix. The elevated risk of second primary cancers was observed within the first 10 years of follow-up. Leukemia and cancers of the salivary gland, kidney, prostate, lung, and breast had the most significantly elevated risks as secondary cancers and presented as early as during the first 5 years after the initial diagnosis of thyroid cancer. CONCLUSIONS: This is the largest, standardized, population-based study to date using nationwide data from the entire Korean population. The risks of several cancers were elevated significantly during follow-up, thus alerting physicians to pay special attention in their care of patients with thyroid cancer and long-term survivors.
Authors: Seo Young Sohn; Young Nam Kim; Hye In Kim; Tae Hyuk Kim; Sun Wook Kim; Jae Hoon Chung Journal: Endocrine Date: 2017-08-18 Impact factor: 3.633
Authors: Marwan H Adly; Mohamed Sobhy; Mohamed A Rezk; Medhat Ishak; Mahmoud A Afifi; Ayman El Shafie; Mahmoud Ahmed Ali; Wael Zekri; Ahmad Samir Alfaar; Wafaa M Rashed Journal: Int J Clin Oncol Date: 2018-02-28 Impact factor: 3.402
Authors: M Qiu; Y Y Lian; M Lu; B S Wang; X J Tian; J Lu; C Liu; S D Zhang; M Jiang; L L Ma Journal: Beijing Da Xue Xue Bao Yi Xue Ban Date: 2022-08-18
Authors: Carolina C P S Janovsky; Rui M B Maciel; Cleber P Camacho; Rosalia P Padovani; Claudia C Nakabashi; Ji H Yang; Eduardo Z Malouf; Elza S Ikejiri; M Conceição O C Mamone; Jairo Wagner; Danielle M Andreoni; Rosa Paula M Biscolla Journal: Eur Thyroid J Date: 2015-11-24
Authors: Sara J Schonfeld; Lindsay M Morton; Amy Berrington de González; Rochelle E Curtis; Cari M Kitahara Journal: Cancer Epidemiol Date: 2019-12-26 Impact factor: 2.984
Authors: Thomas J Semrad; Qian Li; Melanie Goldfarb; Alison Semrad; Michael Campbell; D Gregory Farwell; Theresa H M Keegan Journal: J Adolesc Young Adult Oncol Date: 2021-01-28 Impact factor: 1.757
Authors: Khalid H Al-Qahtani; Mushabbab Al-Asiri; Mutahir A Tunio; Naji J Aljohani; Yasser Bayoumi; Hussain Al-Hussain; Ahmad M Maklad Journal: Saudi Med J Date: 2015-04 Impact factor: 1.484